Podcasts about clinical trials

After years of carrying the weight of lead, Shannon and Cooper find a path out from under the darkness and into the sunlight.LEAD: how this story ends is up to us is an audio docudrama series that tells the true story of one child, his mysterious lead poisoning, and his mother's unwavering fight to keep him safe. A true story written by Shannon Burkett. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.Lead was produced by Shannon Burkett. Co-produced by Jenny Maguire. Featuring Amy Acker, Tom Butler, Dennis T. Carnegie, James Carpinello, Geneva Carr, Dann Fink, Alice Kris, Adriane Lenox, Katie O'Sullivan, Greg Pirenti, Armando Riesco, Shirley Rumierk, Thom Sesma, and Lana Young. Music by Peter Salett. “Joy In Resistance” written by Abena Koomson-Davis and performed by Resistance Revival Chorus. Casting by Alaine Alldaffer and Lisa Donadio. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dean's Chat hosts, Drs. Jensen and Richey, welcome Dr. Laura Brinker to the podcast! Laura Brinker, DPM, was previously a Vice President of Clinical Affairs at Paragon 28, where she drove innovation in foot and ankle surgical solutions. She now has a consulting firm to address advancements of medical devices, regulatory compliance, and clinical trials. With a background in Mechanical Engineering from Purdue and a DPM from Temple University, she completed her residency at the University of Louisville/Jewish Hospital. Dr. Brinker has combined private practice experience, clinical research, and engineering expertise to advance podiatric surgery and medical device development. Enjoy this entrepreneurial discussion with a young leader in our profession!

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction (0:00) A Farmer with Myeloma; Is Myeloma the New Chronic Myeloid Leukemia? (2:06) Clinical Trials (12:34) Chimeric Antigen Receptor Therapy (16:11) Bispecific Antibodies (21:38) Antibody-Drug Conjugates; a Patient on Belantamab Mafodotin for 3 Years (30:45) Treatment Options for Relapsed Disease (40:46) Neuropathy (44:43) Alternative Therapies (48:36) 164 Questions (53:20) CME information and select publications

As global regulatory expectations evolve, biotech sponsors face growing pressure to make smarter, earlier decisions about where and how to run their trials. In this episode, Novotech experts Renita Hite (Director of Regulatory Affairs, Drug Development Consulting) and Scott Schliebner (Global Head of Drug Development Consulting) join moderator Meredith Landry to discuss how early-stage sponsors can adapt to shifting FDA initiatives, accelerated global pathways, and increasing demands for regulatory flexibility. They explore: How new FDA initiatives—like AI-driven reviews, user fee changes, and the National Priority Voucher—are reshaping IND strategy Why sponsors should design trials with global data packages in mind from day one Accelerated and early access pathways that can speed startup and market entry How CROs are evolving to help sponsors prioritize markets and build regulatory flexibility If you're planning trials for 2025 and beyond, this conversation will help you prepare for what's next—and position your program for long-term success. About This Episode This episode is the final installment (4 of 4) in the series “Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials”, featuring insights from Novotech on evolving trends impacting global clinical development. Catch up on earlier episodes: [Part 1: Navigating Regulatory Changes & Market Dynamics] [Part 2: Navigating Regulatory & Market Shifts] [Part 3: Navigating Regulatory Changes & Market Dynamics]

Small cell lung cancer was once considered one of the most challenging diagnoses in oncology. But today, groundbreaking treatments are transforming patient outcomes and rewriting survival stories. Discover how immunotherapy, T-cell engagers, CAR T-cell therapy, and antibody drug conjugates are moving from clinical trials to standard care, offering patients years of disease control and genuine hope for the future. Featuring insights from Dr. Jacob Sands, thoracic oncologist at Dana-Farber Cancer Institute, and inspiring patient advocate Wendy Brooks, who shares her powerful journey from early detection through cutting-edge clinical trials, proving that advocacy and hope can change everything. Guests: Dr. Jacob Sands, Oncologist, Dana-Farber Cancer Institute Courtney Mantz, Program Manager II, SCLC Program, Dr. Sands' Assistant. Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology Wendy Brooks, Patient Advocate Show Notes | Transcript | Watch Video

Dr. Hoffman continues his conversation with Stephen T. Talcott, Ph.D., Professor of Food Chemistry, Department of Food Science and Technology at Texas A&M University, about the powerful health benefits of the muscadine grape.

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman discusses the health benefits of Muscadine grapes with Dr. Stephen Talcott, a PhD chemist and professor of Food Chemistry at Texas A&M. The conversation delves into the unique biochemical properties of Muscadine grapes, their polyphenol content, and their potential health benefits compared to other fruits like Acai and common grapes. They also explore the bioavailability of nutrients, the role of phytoalexins, and the benefits of Muscadine grape-derived products. Dr. Talcott shares his insights on ongoing research at Wake Forest University, the advantages of Muscadine grape products for chemotherapy patients, and the benefits of using these products as natural health supplements. The episode highlights various Muscadine grape products available from Mighty Muscadine and Vinetastic, including juices, supplements, and topical applications, and offers a special discount code for listeners.

Episode Title: Episode #63, Wearables: the Good, Bad, and Ugly, with Don Matutina, MS Don's Bio: Don Matutina, MS, is a research scientist and health professional with a multifaceted background in dietetics, exercise physiology, and culinary arts. He earned his BS in Dietetics and MS in Nutrition from the University of Kentucky and holds a culinary arts certificate (Certified Culinarian). Don is a Level 1 Sommelier with advanced training and has served as a research coordinator on multiple clinical trials, specializing in exercise physiology and wearable technology. His expertise bridges science, nutrition, and practical lifestyle interventions, providing unique insight into the applications and pitfalls of modern wearable devices. Description: In this episode of the Elevate Yourself podcast, Rob sits down with Don Matutina, MS, to explore the rapidly evolving world of wearable technology. Don breaks down the “good, bad, and ugly” of wearables, helping listeners understand what these devices can really measure, their limitations, and the potential unintended consequences of tracking every step, heart beat, and calorie burned. Listeners will learn the differences between consumer wearables and research-grade devices, insights from clinical trials Don has coordinated, and the ways wearables can enhance—or sometimes complicate—our health and fitness journeys. Don also shares his perspective on privacy, AI, and emerging technology concerns in the wearable space, offering practical guidance for anyone looking to integrate these tools into their daily routine. Topics Covered: Don's Background and Expertise Learn about Don's journey from dietetics and culinary arts to exercise physiology and clinical research, including his work as a research coordinator on multiple trials and his unique blend of science, nutrition, and lifestyle experience. Understanding Wearables Don defines what constitutes a wearable device, explains how most people use them, and contrasts consumer wearables with research-grade devices. Clinical Trials and Insights Explore Don's experience using wearables in research studies, including which devices were used, what metrics were tracked, and the key findings that emerged. The Good, Bad, and Ugly of Wearables Learn about the benefits of wearables, potential unintended consequences, and challenges related to accuracy, privacy, and AI integration. Rapid Fire – “One Thing” Don shares practical and personal insights on what elevates his science and life, from daily habits to recent accomplishments. Learn More: Don Matutina research article on exercise Athletic Brewing: athleticbrewing.com – Use code ELEVATE30 for 30% off your first online order.

Send us a textDr. Michael Koren is joined by Dr. Ezekiel "Zeke" Emanuel, an oncologist, bioethicist, and former White House advisor. Dr. Emanuel talks about his enduring interest in bioethics and the importance of ethics in areas like clinical research. The two doctors also talk about shared experiences at Harvard Medical School and Dr. Emanuel's contributions to bioethics in healthcare and research over his career. They close Part 1 of this conversation with Dr. Emanuel laying out the disparities between US healthcare spending and health outcomes.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

The deficits from the lead poisoning continue to intensify, Shannon channels her anger and grief into holding the people who hurt her son responsible.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.EP4 features Eboni Booth, Sasha Eden, Kevin Kane, April Matthis, Alysia Reiner, and Mandy Siegfried. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

View the Show Notes For This Episode Dr. Andrea McBeth discusses how Stool-derived Postbiotics can restore gut health with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights   In this episode of the Rational Wellness Podcast, host Dr. Ben White discusses postbiotics with Dr. Andrea McBeth, a naturopathic clinician and expert in functional gastroenterology and the microbiome. Dr. McBeth shares insights into her work with fecal microbial transplants and her development of the pheno-biotic supplement made from sterilized fecal matter. The conversation dives into the benefits of postbiotics for various gastrointestinal conditions and overall gut health, the complexities of bile acids and their roles in the body, and the emerging understanding of the microbiome's impact on brain and immune function. Dr. McBeth also highlights the stringent criteria for selecting stool donors for her supplements and announces an innovative partnership for clinical trials to gather more data on the effectiveness of postbiotics.     00:29 Meet Dr. Andrea Macbeth: Expert in Functional Gastroenterology 01:26 The Science and Benefits of Fecal Microbial Transplants 04:50 Exploring Bile Acids and Their Clinical Importance 10:02 Understanding Prebiotics, Probiotics, and Postbiotics 12:28 The Development and Benefits of Sterilized Postbiotic Products 14:36 The Apollo Wearable: Managing Stress and Improving Sleep 16:07 How Postbiotics Enhance Gut Health and Overall Wellbeing 28:01 The Role of the Microbiome in Immune Education 29:02 Postbiotics and Their Complementary Role 31:51 Clinical Trials and Data Collection 32:58 Dosage Recommendations and Usage 35:52 Probiotics vs. Fecal Microbiota Transplantation (FMT) 42:20 Misconceptions About the Gut Microbiome 48:19 Sourcing and Criteria for Donor Stool 50:04 Conclusion and Final Thoughts       ___________________________________________________________________ Dr. Andrea McBeth is the founder and CEO of Thaena, a pioneering microbiome therapeutics company. She has a Bachelor's in Biochemistry, focusing on molecular biology, and a Doctorate in Naturopathic Medicine. Early in her career, Andrea directed her ND clinical practice toward functional GI disorders and autoimmunity, launching one of the first stool banks for fecal microbiota transplantation to treat Clostridioides difficile infections.  Driven by the interface between gut microbes and human health, Andrea invented ThaenaBiotic, the first human-derived postbiotic supplement. The website is Thaena.com. Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

Clinical trials are vital to offering and developing the most effective treatment options. However, there are large disparities in enrollment across race, ethnicity, geography, and type of cancer care center. Mary Bird Perkins Cancer Center in Baton Rouge, LA uses local partnerships, culturally tailored outreach, and workforce innovation to drive sustainable and equitable participation in clinical trials. Minorities now make up 21% of their clinical trial participation, surpassing the national average. Following these meaningful gains in attracting local minority populations and underserved communities to take part in clinical trials, the Mary Bird Perkins research team received a grant to further support this work. In this episode of CANCER BUZZ, Victor Lin, MD, PhD, research medical director at Mary Bird Perkins Cancer Center, shares strategies for success in their community, including awareness campaigns and partnerships. CANCER BUZZ also speaks with TaeJeanne “TJ” Taylor-Lawrence, RN, registered nurse and patient navigator, about building relationships and supporting patients in clinical trials.     “We really, really have to be thinking, from a trial design standpoint, about the barriers that we're throwing up in the name of trying to keep the science and the data clean.” - Victor Lin, MD, PhD    “There's been this long-standing perception that cancer clinical trials are really the domain of only academic cancer centers. But I think increasingly we're finding that ... community cancer centers can be more nimble and are perfectly capable of running the same trials and seeing these patients where they live.” - Victor Lin, MD, PhD    “I think that representation builds trust. If people don't see themselves in this process, whether it's in the data, whether it's in the staff, or any of the outreach programs that we have, they're just less likely to believe that this is for them. In my community, black and brown communities especially, I think there's a deep need to feel seen, respected, and understood. When a patient sees someone that looks like them or shares their background talking about clinical trials, I think that that shifts the energy.” - TaeJeanne “TJ” Taylor-Lawrence, RN    “If the research does not reflect all of us, the solutions won't either.” - TaeJeanne “TJ” Taylor-Lawrence, RN    Victor Lin, MD, PhD Research Medical Director Mary Bird Perkins Cancer Center Baton Rouge, LA   TaeJeanne “TJ” Taylor-Lawrence, RN Registered Nurse Mary Bird Perkins Cancer Center Baton Rouge, LA   Resources: ACCC Community Oncology Research Institute (ACORI) Bringing Cancer Research to the Community:  Strategic Approaches to Representative Oncology Clinical Trial Design Mary Bird Perkins Cancer Center Receives $400,000 Grant to Continue Expansion of Nationally-Recognized Clinical Trials Program

In this episode of WCG Talks Trials, Cristin MacDonald, Doug Mayer, and Tyler Bye discuss how Software as a Service (SaaS) solutions are democratizing the clinical trial landscape. Learn how SaaS platforms are enabling organizations of all sizes to leverage cutting-edge technology, improving collaboration, standardization, and data security throughout the clinical research process. The team shares the benefits of adopting SaaS, practical insights for successful implementation, and highlights the pivotal role of technology partnerships in supporting innovation and research efficiency. Tune in to discover how your organization can optimize clinical trials and accelerate research impact with SaaS technology.

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

In this episode of the Heart podcast, Digital Media Editor, Professor James Rudd, is joined by Professor Vijay Kunadian from the University of Newcastle and Sarah Brown, a patient with heart disease, who are both co-authors on a consensus statement. They discuss the state of research participation among females in each area of cardiovascular disease, identify barriers to research for females in each area, and finally, describe strategies to increase female involvement in cardiovascular research. If you enjoy the show, please leave us a positive review wherever you get your podcasts. It helps us reach more people - thank you! Link to published paper: Paper - https://heart.bmj.com/content/early/2025/05/28/heartjnl-2024-325545 Editorial - https://heart.bmj.com/content/early/2025/05/28/heartjnl-2025-325979

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

Hear about cutting-edge advances in regenerative medicine, from lab breakthroughs to patient impact. Catriona Jamieson, MD, PhD, introduces efforts at the Sanford Stem Cell Institute to develop therapies that enhance the body's ability to heal itself. Dan Kaufman, MD, PhD, shares progress in cancer immunotherapy using engineered natural killer cells derived from pluripotent stem cells. Karen Christman, PhD, explains how her team creates injectable hydrogels from pig heart tissue to support heart repair and regeneration after a heart attack. Tiffani Manolis highlights industry support for making cell and gene therapies more accessible. Patient advocate Justin Graves describes his life-changing experience receiving a stem cell-based therapy for epilepsy, underscoring the real-world promise of these innovations. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40705]

In this episode I discuss clinical trial simulations. I review concepts of trial simulation including different variability terms and when to use them. I also share my thoughts on 3 different applications used in clinical trial simulation. Links discussed in the show:Trial Simulator Software page Simulx Software page You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Send us a textDr. Michael Koren joins Kevin Geddings to wax nostalgic about the past generation and what has changed for the better and for the worse. They note that there have been improvements in areas like food, but that air travel and the healthcare experience have deteriorated precipitously. They then contrast this with the massive improvements in the clinical research experience, where around 97-99% of participants say they would do another study. Tune in to find out why this is the case with Dr. Koren and Kevin Geddings.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textAssociation of patent ductus arteriosus treatment in extremely low gestational age neonates with two year kidney outcomes: a secondary analysis of the preterm erythropoietin neuroprotection trial (PENUT).Condit PE, Guillet R, Kaluarachchi D, Griffin RL, Menon S, Askenazi DJ, Harer MW.BMC Nephrol. 2025 Mar 19;26(1):138. doi: 10.1186/s12882-025-04065-8.PMID: 40108500 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Unlocking Innovation: The Alzheimer's Insights AI Prize and Its Impact on Healthcare There are currently more than 55 million people worldwide living with Alzheimer's disease and related dementias. Recent breakthroughs in new treatments and diagnostics provide hope, but there is potential to accelerate the pace of discovery and development. Last year, StartUp Health, in partnership with the Alzheimer's Drug Discovery Foundation's (ADDF) Diagnostics Accelerator (DxA) and Gates Ventures, the private office of Bill Gates, launched the Alzheimer's Moonshot. This initiative breaks down silos and fosters meaningful collaboration between mission-aligned founders, funders, and partners, accelerating progress in preventing, managing, and curing Alzheimer's and related dementias through the support of entrepreneurial innovation. Now, the Alzheimer's Disease Data Initiative (AD Data Initiative) is backing visionary AI solutions to accelerate Alzheimer's research with the launch of a new million-dollar prize competition. The goal is to leverage agentic AI – AI that can plan, reason, and act autonomously – to help drive breakthroughs in  Alzheimer's disease and related dementias research. Gregory Moore, MD, PhD, senior advisor to Gates Ventures and the Alzheimer's Disease Data Initiative, sat down with us to share how you can join the competition to harness AI to radically accelerate Alzheimer's disease research. The Alzheimer's Insights AI Prize offers $1M to the winner for the agentic AI solution that can generate a powerful leap in the pace, scale, and reach of ADRD research. Drawing from his unique background in both engineering and medicine, Dr. Moore discusses how AI could dramatically accelerate drug discovery and clinical trials by up to 50%. The initiative aims to break down traditional research barriers by harmonizing diverse data sets, from genomics to neuroimaging, making breakthroughs more accessible to the global scientific community. The Alzheimer's Insights AI Prize competition semi-finalist teams will be selected to present at a pitch event alongside the Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Diego this December, where innovators worldwide will present their ideas to a distinguished panel of judges from tech, academia, and venture capital. From there, up to three finalist teams will be invited to a final event at the AD/PD International Conference next March in Copenhagen, Denmark. With travel support available for participants, this initiative ensures global accessibility and collaboration. Ready to learn how AI could revolutionize brain health research to potentially detect Alzheimer's earlier, improve treatments, and work toward prevention and cures? Listen to this inspiring episode that bridges technology and medicine in the fight against dementia. Then visit Alzheimer's Insights AI Prize to learn more and apply by September 12, 2025.     Do you want to participate in live conversations with industry luminaries? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Fireside Chats, Expert Office Hours, and Peer Circles are benefits of our Health Moonshot Community Membership. To get involved, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. » Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.

In this Editor's Special Episode of The HemOnc Pulse, Dr. Hira Mian of McMaster University shares expert insights on the evolving treatment landscape for multiple myeloma. From optimizing selinexor use, to understanding long-term MonumenTAL-1 data with talquetamab, to the promise of emerging trispecific antibodies, Dr. Mian highlights the biggest shifts shaping care today.

The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.

In this episode of Stanford Legal, host Professor Pamela Karlan interviews her Stanford Law School colleague Professor Lisa Larrimore Ouellette about actions by the Trump administration that Ouellette says are undermining scientific research and jeopardizing America's longstanding global leadership in medicine and innovation. Drawing on an essay she penned for Just Security, Ouellette explains how decades of bipartisan support for federally funded science—an engine of American innovation since World War II—is now at risk. From canceling grants already approved through peer review, to capping essential “indirect cost” reimbursements, she details how these moves threaten not just labs and universities but also patients, whose clinical trials are being abruptly halted.  Ouellette also highlights a second front in her current scholarship: how drug development policy can be better aligned with public health needs. As a member of a National Academies committee, she recently co-authored a report showing that both private investment and federal funding often fail to prioritize diseases causing the greatest suffering. Links:Lisa Larrimore Ouellette >>> Stanford Law pageThe Trump Administration's Multi-Front Assault on Federal Research Funding  >>> Just Security pageStanford Law's Lisa Ouellette Helps Shape New Report on Drug Development Reform  >>> Stanford Lawyer online featureConnect:Episode Transcripts >>> Stanford Legal Podcast WebsiteStanford Legal Podcast >>> LinkedIn PageRich Ford >>>  Twitter/XPam Karlan >>> Stanford Law School PageStanford Law School >>> Twitter/XStanford Lawyer Magazine >>> Twitter/X(00:00) Research Funding (05:01) The Competitive Grant Process (15:01) Addressing Disease Burden (20:00) Impacts of Stopped Clinical Trials (25:01) The Role of Federal Investment in Innovation 

While AI represents a significant advancement in efficiency for early-stage drug discovery, it won't dramatically change the 90% clinical trial failure rate. Most failures stem from fundamental gaps in biological understanding rather then the processes where AI is able to have the most impact.The discussion highlights AI's strengths and ability to reduce preclinical costs. However, they caution that AI faces significant limitations in predicting complex biological properties like toxicity due to insufficient data, and regulatory acceptance of AI-only safety assessments remains unlikely, meaning traditional clinical trials will continue to be necessary.This episode is presented in partnership with ⁠Cresset⁠.Host⁠⁠⁠⁠⁠⁠⁠⁠Lori Ellis⁠⁠⁠⁠⁠⁠⁠⁠, Head of Insights, BioSpaceGuests⁠Mutlu Dogruel⁠, VP of AI, Cresset⁠Mark Mackey⁠, CSO, CressetDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Dr. Emily Lindley is Assistant Professor of Orthopedics and Director of the Colorado Cannabis Research Consortium. Her team's research aims to identify non-opioid alternatives for the treatment of chronic musculoskeletal pain. One such alternative that has gained increased recognition in recent years is medical cannabis, and her lab is currently studying the health effects of cannabis and cannabinoids for chronic musculoskeletal pain. Dr. Rachael Rzasa Lynn is a board certified in pain medicine physician and is an Associate Professor in the Department of Anesthesiology at the University of Colorado, where she is the Associate Program Director for the Pain Medicine Fellowship. Her research includes investigations in opioid pharmacology and the use of cannabis for chronic pain. Emily and Rachael co-authored a poster presented at the most recent ICRS conference titled, Recruitment Challenges in Clinical Studies of Cannabis During our conversation, we discussed: How recruitment for cannabis clinical trials differs from traditional clinical trials Why prior experience with cannabis is considered a negative for patient recruitment How legal concerns and stigma can deter cannabis-naive patients from enrolling Why the particiapnt drop out rate is higher in cannabis trials How rescheduling may affect patient recruitment future trials Thanks to This Episode's Sponsor: The Society of Cannabis Clinicians The Society of Cannabis Clinicians' Med Cann conference offers a rare opportunity for clinicians to dive deep into the clinical realities and therapeutic potential of medical cannabis and psychedelics. Designed with healthcare providers in mind, their sessions focus on case-based learning, emerging protocols, and real-world challenges—offering practical insights that can be immediately applied in your practice. Learn more at cannabisclinicians.org and use code "CP15" to receive 15% Off Your Registration Additional Resources Recruitment Challenges in Clinical Studies of Cannabis [Poster] Lindley Lab at the University of Colorado

The trial is evaluating a cell dose that is 50 percent higher than the highest dose used in a previous Phase 2b trial.

Just over two years ago, the FDA issued its first draft guidance on clinical trials with psychedelic drugs. Now, HHS has hired a dedicated psychedelics advisor. This week, Reunion Neuroscience reported a mid-stage success with its short-acting psychedelic drug in postpartum depression.At a moment of increasing momentum – both in terms of research, funding and commercial promise – behind psychedelics, it's worth checking in with one of the leaders in the space: Cybin, a clinical-stage biopharma.In November, Cybin reported positive Phase 2 data for its major depressive disorder drug and has its sights set on next steps in the regulatory approval process.Pharma Editor Lecia Bushak brings us a conversation with Cybin CEO Doug Drysdale about "second-generation" psychedelics and how they are impacting the mental health treatment space.For our Trends segment, we're talking about recent updates to health data sharing on the federal level. Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

The effects of the neurotoxin are taking their toll on Cooper as Shannon desperately tries to navigate the severity of their new reality.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper Burkett.E43 features Jenny Maguire, JD Mollison, Laith Nakli, Deirdre O'Connell, Carolyn Baeumler, Zach Shaffer, and Monique Woodley. Casting by Alaine Alldaffer and Lisa Donadio. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Enriqueta Felip, MD, PhD - Targeting TROP2 in Advanced NSCLC: What Do We Know From Recent Clinical Trials?

Send us a textDr. Michael Koren joins Kevin Geddings to explain how having a conversation with a medical professional who is tuned into your personal situation can help you understand the confusing and sometimes counterintuitive world of medical information. Cardiologist Dr. Koren uses the examples of coronary calcium scores and total cholesterol levels, which must be interpreted in the context of individual factors, such as age and HDL/LDL ratio. They then discuss clinical research and how the experience in a clinical research setting is one of shared knowledge, where medical professionals take the time to explain everything you need to know about your health.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textEarly Neurodevelopment of Extremely Preterm Infants Administered Autologous Cord Blood Cell Therapy: Secondary Analysis of a Nonrandomized Clinical Trial.Zhou L, Razak A, McDonald CA, Yawno T, McHugh DT, Whiteley G, Connelly K, Sackett V, Miller SL, Jenkin G, Novak I, Hunt RW, Malhotra A.JAMA Netw Open. 2025 Jul 1;8(7):e2521158. doi: 10.1001/jamanetworkopen.2025.21158.PMID: 40608334 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Send us a textWhole-Body Hypothermia for Neonatal Encephalopathy in Preterm Infants 33 to 35 Weeks' Gestation: A Randomized Clinical Trial.Faix RG, Laptook AR, Shankaran S, Eggleston B, Chowdhury D, Heyne RJ, Das A, Pedroza C, Tyson JE, Wusthoff C, Bonifacio SL, Sánchez PJ, Yoder BA, Laughon MM, Vasil DM, Van Meurs KP, Crawford MM, Higgins RD, Poindexter BB, Colaizy TT, Hamrick SEG, Chalak LF, Ohls RK, Hartley-McAndrew ME, Dysart K, D'Angio CT, Guillet R, Kicklighter SD, Carlo WA, Sokol GM, DeMauro SB, Hibbs AM, Cotten CM, Merhar SL, Bapat RV, Harmon HM, Sewell E, Winter S, Natarajan G, Mosquera R, Hintz SR, Maitre NL, Benninger KL, Peralta-Carcelen M, Hines AC, Duncan AF, Wilson-Costello DE, Trembath A, Malcolm WF, Walsh MC; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.JAMA Pediatr. 2025 Apr 1;179(4):396-406. doi: 10.1001/jamapediatrics.2024.6613.PMID: 39992674 Free PMC article. Clinical Trial.EBNEO Commentary: Is Therapeutic Hypothermia Beneficial to Infants Born Between 33 and 35 Weeks Gestation?Spahic H, Zoubovsky SP, Dietz RM.Acta Paediatr. 2025 Jul;114(7):1742-1743. doi: 10.1111/apa.70098. Epub 2025 Apr 18.PMID: 40251839 No abstract available.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Claire Riches, Vice President, Clinical Solutions at Citeline. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering: Being involved in the clinical development and commercial launch of a little mega-blockbuster, called... Viagra. Her first exposure to outsourcing at a small biotech, and the importance of partnerships in progressing the pipeline. Ignoring the pharma industry snobbery, and opting to move into the fast and varied world of CROs. Timeless sponsor and provider partnership tips, including the importance of aligned intentions, especially with biotechs. How are the tailwinds for rare diseases, meeting unmet patient needs, AI/data, and personalised medicines driving demand at Citeline? With over 30 years' experience in the life science sector, Claire is a passionate advocate of bringing drug development to life. Having worked in large pharma, biotech and the CRO space, Claire uses her platform to raise awareness of the challenges the industry is facing, and how as a collective voice, we can solve big, challenging questions. She believes strongly in the need to ask questions of the industry to drive change, which in turn drives innovation and growth. Claire speaks regularly through various forums on the topics of Women in Science, Impacts of Politics and Economics on Drug Development and Drug Access, and Evolution and Efficiency of Drug Development pathways. She is currently focused on levelling the playing field for the Biotech industry via her podcast Small Biotech, Big Decisions | Citeline   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!

Featuring perspectives from Dr Natalie S Callander and Dr Sagar Lonial, including the following topics:  Introduction: Multiple Myeloma — 2005 to 2025 (0:00) Questions from the Beginning (7:53) Choosing Options (13:54) Clinical Trials (18:03) Neuropathy (23:55) Chimeric Antigen Receptor (CAR) T-Cell Therapy (28:40) Bispecific Antibodies (35:18) Antibody-Drug Conjugates (43:08) Interacting with the Oncology Team (51:47) Other Questions (57:30) Educational and presenter information

Neurologist Michelle Monje studies the close relationship between cancer and the nervous system, particularly in an aggressive brain cancer that often strikes in childhood. Her research shows that the cancer cells are electrically integrated into the brain itself and these connections actually help the cancer to grow. Monje and collaborators have now developed an immunotherapy that has shown great promise in mice and early human trials. One patient had a “complete response” and is cancer-free four years after treatment, Monje tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michelle MonjeConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michelle Monje, a professor of pediatric neurology at Stanford University.(00:03:39) Focus on Cancer ResearchMonje's clinical observations led to exploring cancer-neuron interactions.(00:05:28) Neurons and Glial CellsThe role of neurons and glial cells in brain function and disease.(00:08:32) Gliomas in ChildrenAn overview of gliomas and their origins in glial precursor cells.(00:10:12) Rethinking Brain Cancer BehaviorHow gliomas don't just grow—they integrate with brain circuits.(00:14:49) Mechanisms of Tumor GrowthTwo primary mechanisms by which cancer exploits the nervous system.(00:16:32) Synaptic Integration of Cancer CellsThe discovery that glioma cells form synapses with neurons.(00:20:06) CAR T-Cell TherapyAdapting CAR T-cell immunotherapy to target brain tumors.(00:22:52) Targeting GD2 AntigenIdentification of a surface marker enables precision CAR T-cell therapy.(00:24:35) Immune Access to the BrainThe ability of CAR T-cells to reach the brain, despite prior understanding.(00:26:16) First Clinical Trial ResultsThe significant tumor reduction and response from CAR T-cell therapy.(00:28:21) Combined TherapiesPairing immune therapy with neural signaling blockers for better outcomes.(00:30:35) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

In this episode of It Takes Balls, 29-year-old Christopher Beck shares his intense and ongoing fight against a rare and aggressive form of testicular cancer - one that didn't even begin in his testicle.Christopher opens up about the strange onset of symptoms that eventually led to a stunning diagnosis: embryonal carcinoma presenting as a retroperitoneal mass. Despite having no tumors in his testicles, pathology confirmed testicular cancer, placing him in a rare category of patients with extragonadal germ cell tumors.What follows is a relentless journey: four rounds of BEP chemotherapy, followed by a post-chemo RPLND at Indiana University. Christopher thought he was in the clear until new scans revealed a recurrence a few months later. What began as one battle turned into two, then three. He entered a clinical trial and underwent high-dose chemotherapy with stem cell rescue.Now, Christopher is enrolled in a cutting-edge CAR T-cell therapy trial - a hopeful step forward. He shares candid reflections on the mental weight of recurrence, the isolation of dealing with a rare cancer, and the importance of keeping faith while making space for both grief and gratitude.Christopher also speaks openly about how cancer reshaped his identity, tested his relationships, and pushed him to live more deliberately, with purpose, presence, and patience.Join The Ball Room:https://www.testicularcancerawarenessfoundation.org/theballroomWant to be a guest? Apply here:https://www.testicularcancerawarenessfoundation.org/it-takes-balls-submissionsFollow Testicular Cancer Awareness Foundation:⁠https://www.testescancer.orghttps://www.twitter.com/testescancer⁠⁠https://www.instagram.com/testescancerhttps://www.facebook.com/tca.orgFollow Steven Crocker: https://www.twitter.com/stevencrockerhttps://www.instagram.com/stevencrockerhttps://www.facebook.com/steven.crocker2Connect with Christopher:beck.r.christopher@gmail.comTheme song: No Time Like Now - Tom Willner www.tomwillner.com

Send us a textDr. Michael Koren Joins Kevin Geddings to discuss how the current political situation in Washington, D.C. is interfering with clinical research. They discuss the Vaxart trial, that is looking at the next generation of oral COVID vaccines, and how it has been affected by the Trump administration's inconsistent orders regarding vaccines. Dr. Koren points out that the Vaxart trial doesn't actually use mRNA and is poised to be a solution beyond this technology, but that the administration has stopped (at least temporarily) this research anyway.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

In this episode of SurgOnc Today, Drs. Oluwadamilola "Lola" Fayanju and Jose Trevino moderate a conversation with Drs. Ugwuji Maduekwe and Rebecca Snyder on the importance of patient diversity in clinical trials as they also provide  systemic, investigator-led, and patient-level strategies to facilitate enrollment of diverse trial participants.

Send us a textRadiologist Sue Jane Grosso-Rivas, MD joins cardiologist and clinical researcher Michael J. Koren, MD to share her inspiring journey from aspiring secretary to Medical Co-Director of Breast Imaging at Summit Health. The doctoral duo discuss how Dr. Grosso-Rivas's career was shaped by a school counselor who recognized her potential and encouraged her ambition.Dr. Grosso-Rivas explains the fundamentals of breast mammography: when patients should begin screening, and how to ensure high-quality care for breast cancer prevention. She then explores what happens if mammography finds an abnormality, including if it is benign, suspicious, or indicative of cancer.This is part one of a two-part series.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

As the lead wreaks havoc on Cooper's development, Shannon searches for answers. Desperate to get a handle on what was happening to her son, she grabs onto a lifeboat - nursing school. Andy tries to piece together the past to make sense of the present.LEAD how this story ends is up to us is a true story written and produced by Shannon Burkett. Co-produced by Jenny Maguire. Directed by Alan Taylor. Starring Merritt Wever, Alessandro Nivola, Cynthia Nixon, and Cooper BurkettEP2 features Keith Nobbs and Frank Wood. Music by Peter Salett. Sound Design by Andy Kris. Recording Engineer Krissopher Chevannes. Casting by Alaine Alldaffer and Lisa Donadio.For corresponding visuals and more information on how to protect children from lead exposure please go to https://endleadpoisoning.org.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Who should participate in a Clinical Trial and why?  Dr. Linda Duska and Claudette Grant from the UVA Comprehensive Cancer Center joined RHV to discuss the myths and facts of clinical trials. Links: UVA Community Outreach & Engagement Clinical Trials Toolkit ClinicalTrials.gov RHV podcast episode on HPV

My guest is Dr. Nirao Shah, MD, PhD, a professor of psychiatry, behavioral sciences and neurobiology at Stanford University School of Medicine. We discuss how the brains of males and females differ and how those differences arise from different genes and hormones during fetal development, in childhood and adulthood. We discuss what drives male- versus female-specific behaviors and how hormonal fluctuations across the lifespan, including puberty, the menstrual cycle, menopause and aging – affect behavior, cognition and health. Additionally, we discuss how biology relates to gender identity and the impact of hormone therapies on brain circuits that regulate mating, parenting and social bonding. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Eight Sleep: https://eightsleep.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00:00 Nirao Shah 00:02:11 Mice, Humans & Brain, Biological Conservation 00:05:25 Hormones, Nature vs Nurture 00:07:13 Biological Sex Differences, Chromosomes & SRY Gene, Hormones 00:16:01 Sponsors: Maui Nui & Eight Sleep 00:19:09 Androgen Mutations, Feminization & Masculinization 00:22:04 SRY Gene; Animals & Sexual Trans-Differentiation 00:27:49 Hormones & Biological Brain Differentiation 00:31:22 Congenital Adrenal Hyperplasia, Androstenedione; Stress & Pregnancy 00:35:56 Genes, Brain Differentiation & Sexual Identity; Congenital Adrenal Hyperplasia 00:43:37 Testosterone, Estrogen & Brain Circuits 00:47:27 Sponsors: AG1 & LMNT 00:50:36 Intersex Individuals, Castration 00:52:23 Female Sexual Behavior, Brain, Testosterone & Pheromones 00:57:58 Identify as Heterosexual or Homosexual, Difference in Hormone Levels? 01:00:42 Gender, Sexual Orientation & Hormones; Hormone Replacement Therapy 01:10:21 Aromatization; Steroid Hormones & Gene Expression 01:15:00 Kids & Changing Gender Identity 01:19:05 Sexual Behavior, Refractory Period & Male Brain, Tacr1 Cells 01:21:31 Sponsor: Function 01:23:19 Hypothalamus, Dopamine, Prolactin, Cabergoline, Libido, Dopamine 01:27:05 Brain Circuits, Aggression & Sexual Behavior 01:32:40 Refractory Period; Age, Testosterone & Libido 01:36:07 Tacr1 Cells in Females, Periaqueductal Gray & Innate Behaviors 01:40:00 Parenting Behaviors & Brain Circuits; Pet Dogs 01:43:12 Oxytocin, Pair Bonding, Vasopressin; Biological Redundancy 01:47:22 Libido, Melanocortin, Tacr1 Neurons; GLP-1 Agonists, Clinical Trials; Kisspeptin 01:56:43 Female Brain Changes, Menstrual Cycle, Pregnancy, Menopause; Estrogen; Men & Hormone Fluctuation? 02:04:10 Life Experience Male vs Female, Sex Recognition, Behaviors & Context 02:16:05 Pain Management; Endocrine Disrupters, Gender Identity 02:21:03 Future Projects 02:24:29 Zero-Cost Support, YouTube, Spotify & Apple Follow & Reviews, Sponsors, YouTube Feedback, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices